The Applied Biosystems TaqPath COVID-19, Flu A, Flu B Combo Kit is a real-time PCR test for the detection and differentiation of RNA from the SARS-CoV-2, influenza A and influenza B viruses in nasopharyngeal and nasal swabs. To help meet the demand for respiratory testing during the overlap of covid-19 and the flu season, the TaqPath COVID-19, Flu A, Flu B Combo Kit is approved for emergency use and available for purchase.
With the overlap of flu season and the novel coronavirus pandemic, it is vital that clinical and public health labs have access to a single test that can simultaneously detect RNA from multiple respiratory viruses. The TaqPath COVID-19, Flu A, Flu B Combo Kit can help labs expand their existing COVID-19 testing menu for respiratory samples while supporting low operational costs and workflow simplicity. The combo kit includes Applied Biosystems Pathogen Interpretive Software to automatically convert genetic analysis data into a readable report, helping reduce risk of user interpretation error.
“We knew that this season’s surge in COVID-19 infections could coincide with cases of influenza and RSV, so we worked quickly to develop a PCR-based diagnostic kit for detecting and differentiating these illnesses simultaneously,” said Mark Smedley, President of Genetic Sciences for Thermo Fisher. “Our kit provides laboratories with the ability to diagnose and monitor the spread of COVID-19 and similar illnesses, which may require different patient management, including quarantining measures.” We are striving to supply the tests you need to meet respiratory testing demand during flu season.
The TaqPath COVID-19, Flu A, Flu B Combo Kit has not been FDA cleared or approved and is only authorized for the duration of the EUA.